Clinical Trials Browser

INDUSTRY × enfortumab vedotin × 30 days × Clear all

NCT04960709 2026-06-04

VOLGA

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT07421700 2026-06-04

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Phase 1/2 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Phase 1 Recruiting

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT04223856 2026-05-29

EV-302

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Urothelial Cancer

NCT06862219 2026-05-28

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Phase 4 Recruiting

Carcinoma, Transitional Cell

NCT05614739 2026-05-19

FORAGER-1

Phase 1 Recruiting

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT07475806 2026-05-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Recruiting

Muscle-invasive Bladder Cancer

NCT06011954 2026-05-14

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Urinary Bladder Neoplasms

NCT07566156 2026-05-11

EV-309

Phase 3 Recruiting

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases